Dishman Carbogen Amcis Ltd

Dishman Carbogen Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Dishman Carbogen Amcis Ltd

₹ 221 0.68%
19 Apr - close price
dishmangroup.com BSE: 540701 NSE : DCAL
About

Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries.[1]

Key Points

Business Segments
CRAMS Vertical (~77% of total revenues)[1]
The company is an integrated Contract Research & Manufacturing Services (CRAMS) player with strong capabilities across the value chain. It assists drug innovators in development and optimization of processes for novel drug molecules in various stages of the development process. [2]
Presently, the company has a total of 27 commercialized molecules and 17 molecules in phase-3 (last stage) of manufacturing optimization. During the year 3 new molecules were commercialized. [3]
It earns ~83% of CRAMS revenues from Switzerland, France & China. [4]

Website BSE NSE
  • Market Cap ₹ 3,466 Cr.
  • Current Price ₹ 221
  • High / Low ₹ 283 / 113
  • Stock P/E
  • Book Value ₹ 368
  • Dividend Yield 0.00 %
  • ROCE 1.03 %
  • ROE -0.15 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Stock is trading at 0.60 times its book value
  • Company's working capital requirements have reduced from 113 days to 89.6 days

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 7.32% over past five years.
  • Company has a low return on equity of -0.76% over last 3 years.
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
469 529 551 459 562 569 541 614 640 619 723 587 651
406 441 450 360 453 547 452 535 526 567 602 526 610
Operating Profit 63 88 101 99 110 22 88 79 114 51 122 61 41
OPM % 13% 17% 18% 22% 19% 4% 16% 13% 18% 8% 17% 10% 6%
9 -16 10 7 19 -8 6 9 4 -39 7 5 6
Interest 14 9 12 14 15 16 19 20 22 24 28 27 33
Depreciation 79 77 75 74 75 84 75 80 50 76 70 75 80
Profit before tax -22 -14 24 19 38 -85 -0 -12 46 -88 29 -36 -66
Tax % 27% -879% 33% 40% 8% 48% 1,437% 18% -3% 19% 42% -13% 10%
-16 -135 16 11 35 -45 4 -10 47 -71 17 -41 -60
EPS in Rs -1.02 -8.61 1.02 0.71 2.26 -2.85 0.26 -0.64 3.00 -4.51 1.08 -2.61 -3.80
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
1,031 1,714 1,695 2,059 2,044 1,912 2,141 2,413 2,580
830 1,261 1,249 1,507 1,540 1,638 1,809 2,081 2,304
Operating Profit 201 452 445 552 503 274 331 332 275
OPM % 20% 26% 26% 27% 25% 14% 15% 14% 11%
14 26 46 54 39 16 29 -20 -21
Interest 56 49 49 57 62 48 57 86 113
Depreciation 69 214 211 240 283 308 308 281 302
Profit before tax 91 216 231 309 197 -65 -4 -55 -161
Tax % 12% 33% 33% 32% 20% -154% 524% 45%
80 145 155 210 159 -165 18 -30 -154
EPS in Rs 9.58 13.03 10.10 -10.53 1.15 -1.90 -9.84
Dividend Payout % 0% 0% 0% 2% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 7%
3 Years: 6%
TTM: 9%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -1121%
Stock Price CAGR
10 Years: %
5 Years: 0%
3 Years: 15%
1 Year: 65%
Return on Equity
10 Years: %
5 Years: 1%
3 Years: -1%
Last Year: 0%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 16 0 32 32 31 31 31 31 31
Reserves 863 4,814 5,075 5,347 5,684 5,667 5,518 5,778 5,739
868 950 1,095 1,042 1,357 1,589 1,830 2,209 2,308
334 811 967 899 1,121 1,068 1,255 1,421 1,422
Total Liabilities 2,081 6,574 7,169 7,321 8,193 8,356 8,634 9,439 9,501
1,012 4,852 5,066 5,098 5,678 5,698 5,773 6,188 6,364
CWIP 307 133 151 175 234 486 780 1,043 909
Investments 1 40 196 167 191 172 324 249 145
761 1,550 1,757 1,881 2,091 2,000 1,758 1,959 2,083
Total Assets 2,081 6,574 7,169 7,321 8,193 8,356 8,634 9,439 9,501

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
203 303 226 282 585 513 355 220
-231 -107 -297 -169 -442 -380 -619 -448
25 -137 78 -102 -98 -11 130 250
Net Cash Flow -3 59 7 11 46 122 -133 22

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 60 61 96 79 103 80 81 89
Inventory Days 272 473 525 496 462 402 526 574
Days Payable 172 95 201 176 226 132 158 157
Cash Conversion Cycle 160 439 419 399 340 350 449 506
Working Capital Days 49 117 129 135 124 135 115 90
ROCE % 5% 6% 4% 0% 1% 1%

Shareholding Pattern

Numbers in percentages

4 Recently
Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32%
6.38% 5.91% 4.40% 4.60% 5.50% 5.85% 6.20% 7.20% 9.34% 8.90% 8.80% 8.60%
8.94% 6.75% 6.15% 6.31% 6.91% 6.63% 4.26% 3.86% 2.55% 3.13% 3.51% 3.68%
25.36% 28.01% 30.13% 29.77% 28.26% 28.19% 30.22% 29.61% 28.79% 28.65% 28.37% 28.39%
No. of Shareholders 58,73854,07760,72654,66256,32256,98659,65461,17556,58356,22156,27252,336

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls